Overview of Charcot-Marie-Tooth disease type 1A

被引:16
|
作者
Thomas, PK
机构
[1] Royal Free & Univ Coll Med Sch, Sch Med, Dept Clin Neurosci, London NW3 2PF, England
[2] UCL, Inst Neurol, London WC1E 6BT, England
来源
CHARCOT-MARIE-TOOTH DISORDERS | 1999年 / 883卷
基金
英国惠康基金;
关键词
D O I
10.1111/j.1749-6632.1999.tb08560.x
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Type 1A CMT disease is most commonly due to a segmental duplication on chromosome 17p11.2, leading to the presence of an extra copy of the gene for peripheral myelin protein 22 (PMP22). Inheritance is autosomal dominant in pattern. Analysis of nerve biopsies suggests that the disorder is caused by increased gene dosage. Occasionally CMTIA results from point mutations in the PMP22 gene. Onset of symptoms in cases with a duplication is usually in the first decade of Life; slowing of nerve conduction velocity is evident from the age of 2 years. Active demyelination is restricted to childhood. it leads to hypertrophic "onion bulb" changes and is accompanied and followed by progressive axonal loss. The commonest clinical phenotype is the CMT syndrome with distal muscle wasting and weakness, tendon areflexia, usually mild sensory loss, and foot deformity, Other phenotypes include the Roussy-Levy syndrome, in which postural tremor and ataxia are associated, and cases with severe distal sensory loss and acrodystrophic changes.
引用
收藏
页码:1 / 5
页数:5
相关论文
共 50 条
  • [31] Preimplantation genetic diagnosis for Charcot-Marie-Tooth disease type 1A
    De Vos, A
    Sermon, K
    De Rijcke, M
    Goossens, V
    Henderix, P
    Van Ranst, N
    Platteau, P
    Lissens, W
    Devroey, P
    Van Steirteghem, A
    Liebaers, I
    MOLECULAR HUMAN REPRODUCTION, 2003, 9 (07) : 429 - 435
  • [32] Driving Simulator Performance in Charcot-Marie-Tooth Disease Type 1A
    Jerath, Nivedita U.
    Aksan, Nazan
    Dawson, Jeffrey D.
    Rizzo, Matthew
    Uc, Ergun Y.
    Shy, Michael E.
    SAE INTERNATIONAL JOURNAL OF TRANSPORTATION SAFETY, 2019, 7 (01) : 31 - 39
  • [33] Neurofibromatosis type 1 associated with Charcot-Marie-Tooth type 1A
    Koc, Filiz
    Guzel, A. Irfan
    JOURNAL OF DERMATOLOGY, 2009, 36 (05) : 306 - 311
  • [34] A gene silencing approach to treat Charcot-Marie-Tooth disease type 1A
    Stavrou, Marina
    Sargannidou, Irene
    Kagiava, Alexia
    Richter, Jan
    Tryfonos, Christina
    Karaiskos, Christos
    Lapathitis, George
    Christodoulou, Christina
    Kleopa, Kleopas
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2018, 23 (04) : 291 - 292
  • [35] Utility of Charcot-Marie-Tooth Neuropathy Score in Children With Type 1A Disease
    Haberlova, Jana
    Seeman, Pavel
    PEDIATRIC NEUROLOGY, 2010, 43 (06) : 407 - 410
  • [36] Genotype-phenotype study of Charcot-Marie-Tooth disease type 1A
    Mukhamedzyanov, R
    Laura, M
    Blake, J
    Manji, H
    Reilly, M
    JOURNAL OF NEUROLOGY, 2004, 251 : 140 - 140
  • [37] Prevalence and characterization of pain in patients with Charcot-Marie-Tooth disease type 1A
    Azevedo, Helen
    Costa, Henrique
    Davidovich, Eduardo
    Pupe, Camila
    Moreira Nascimento, Osvaldo Jose
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2021, 79 (05) : 415 - 419
  • [38] PAIN AND SMALL FIBER FUNCTION IN CHARCOT-MARIE-TOOTH DISEASE TYPE 1A
    Laura, Matilde
    Hutton, Elspeth J.
    Blake, Julian
    Lunn, Michael P.
    Fox, Zoe
    Pareyson, Davide
    Solari, Alessandra
    Radice, Davide
    Koltzenburg, Martin
    Reilly, Mary M.
    MUSCLE & NERVE, 2014, 50 (03) : 366 - 371
  • [39] CHARCOT-MARIE-TOOTH DISEASE TYPE 1A - MUTATIONAL MECHANISMS AND CANDIDATE GENE
    PATEL, PI
    CURRENT OPINION IN GENETICS & DEVELOPMENT, 1993, 3 (03) : 438 - 444
  • [40] Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A
    Krajewski, KM
    Lewis, RA
    Fuerst, DR
    Turansky, C
    Hinderer, SR
    Garbern, J
    Kamholz, J
    Shy, ME
    BRAIN, 2000, 123 : 1516 - 1527